Modena
-
Moderna, Inc.(MRNA) Q3: EPS 0.38 USD (above forecast), Revenue 1.31B USD (above forecast)
Moderna, Inc.(MRNA) Q3 EPS: 0.38 USD; Forecast -1.1 USD Revenue: 1.31B USD; Forecast 890.25M USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-11-06
-
Yahoo Finance analyst recommends Amgen over Moderna for 2026, citing Amgen's stability and profitability against Moderna's pipeline risks
The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of ap
-
Ron Baron's Bamco Fund Opened New Positions in Fortune Brands Innovations (FBIN) and Harrow (HROW) in Q2 2026, After Buying Moderna Before Its Near Tripling
Ron Baron's Bamco Fund Opened New Positions in Fortune Brands Innovations (FBIN) and Harrow (HROW) in Q2 2026, After Buying Moderna Before Its Near Tripling
-
Moderna's stock doubles on promising cancer-vaccine results
The vaccine candidate, developed with Merck, is an mRNA therapy paired with the cancer drug Keytruda. It helped melanoma patients live longer in a late-stage trial, marking the first Phase 3 data for
-
Moderna, Inc.(MRNA) Q3: EPS 0.38 USD (above forecast), Revenue 1.31B USD (above forecast)
Moderna, Inc.(MRNA) Q3 EPS: 0.38 USD; Forecast -1.1 USD Revenue: 1.31B USD; Forecast 890.25M USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-11-06
-
Yahoo Finance analyst recommends Amgen over Moderna for 2026, citing Amgen's stability and profitability against Moderna's pipeline risks
The analyst highlights Amgen's veteran status in drug manufacturing, focusing on diverse treatments for chronic conditions, with revenue reaching nearly $36.7 billion in FY 2025 and a net income of ap
-
Ron Baron's Bamco Fund Opened New Positions in Fortune Brands Innovations (FBIN) and Harrow (HROW) in Q2 2026, After Buying Moderna Before Its Near Tripling
Ron Baron's Bamco Fund Opened New Positions in Fortune Brands Innovations (FBIN) and Harrow (HROW) in Q2 2026, After Buying Moderna Before Its Near Tripling
-
Moderna's stock doubles on promising cancer-vaccine results
The vaccine candidate, developed with Merck, is an mRNA therapy paired with the cancer drug Keytruda. It helped melanoma patients live longer in a late-stage trial, marking the first Phase 3 data for
- No data
Modena
24H Trending
-
1
CoinDesk: Nasdaq futures up nearly 2%; Anthropic indicative quotes briefly 24% higher
-
2
Financial Times: Anthropic Discloses Activation of Measures Under 'Responsible Scaling Policy'
-
3
Laprophan has raised $223 million through an IPO on the Casablanca Stock Exchange, marking the largest fundraising deal by an African pharmaceutical company.
-
4
What is the total supply of Zilliqa? Introduction to ZIL Supply and Circulating Supply
-
5
What is AMAZINGTEAM coin, and what is its future development outlook?
-
6
What is the value of SDG token? Is SDG token a good long-term investment?
-
7
Al Jazeera to Iranian military: Three oil tankers reportedly struck by mines and caught fire on the eastern side of the Strait of Hormuz since this morning
-
8
Deltaone via Deutsche Bank: Expects the US dollar to strengthen in the first half of 2027 and remain at high levels throughout the year.
-
9
Which is Better to Mine: Ethereum vs. Bitcoin — Mechanism Evolution and Current Mining Landscape Analysis
-
10
Bloomberg: Zimbabwe Seeks Multilateral Bank Aid to Clear Arrears
Markets Today
Recommended Reading



